Download PDF
CC BY 4.0 · Glob Med Genet 2023; 10(03): 199-204
DOI: 10.1055/s-0043-1771182
Original Article

Molecular Epidemiology of HCV RNA Genotype-3 in Dhaka City, Bangladesh

Md Arifur Rahman
1   Department of Microbiology, Jagannath University, Dhaka, Bangladesh
2   PCRLaboratory, Ibn Sina Diagnostics and Imaging Center, Dhaka, Bangladesh
6   Division of Molecular Diagnosis and Clinical Genetics, BioIcon Academy, Dhaka, Bangladesh
,
Md Monirul Islam
3   PCR & Molecular Diagnosis Section, Labaid Limited (Diagnostics), Dhaka, Bangladesh
6   Division of Molecular Diagnosis and Clinical Genetics, BioIcon Academy, Dhaka, Bangladesh
,
Md Eunus Ali
2   PCRLaboratory, Ibn Sina Diagnostics and Imaging Center, Dhaka, Bangladesh
4   Department of Microbiology and Immunology, BSMMU, Dhaka, Bangladesh
,
Mohammad Ariful Islam
1   Department of Microbiology, Jagannath University, Dhaka, Bangladesh
,
Farhana Afroze
1   Department of Microbiology, Jagannath University, Dhaka, Bangladesh
,
Mohammad Shamim Hossain
5   Department of Biology, University of Copenhagen, Copenhagen, Denmark
6   Division of Molecular Diagnosis and Clinical Genetics, BioIcon Academy, Dhaka, Bangladesh
,
Ahmed Abu Rus'd
1   Department of Microbiology, Jagannath University, Dhaka, Bangladesh
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Hepatitis C virus (HCV) is a causative agent that causes chronic liver diseases worldwide. It is a little, enclosed, single-stranded ribonucleic acid (RNA) virus. The recognition of the pathogenic HCV genotype is critical for the remedy of its sufferers. The aim of this study was to identify the HCV RNA genotype to decide the correct treatment of hepatitis C positive sufferers in Bangladesh. Blood samples were collected from 390 individuals and isolated RNA (60 µg) from blood plasma. Extracted RNA was used for quantitative HCV RNA, and complementary DNA (cDNA) was prepared by polymerase chain reaction (PCR) conducted by reverse transcriptase enzyme. This cDNA amplified in multiplex by RT-PCR, which was performed with specific set of primers. The HCV RNA genotype was detected 297 of 390 patients. Of the 390 test samples, 200 (51.28%) samples were from males and 190 (48.71%) were from females, with age ranging from 5 to 78 years. In all, 166 of 200 male samples and 131/190 female samples were found positive for HCV. Of these 390 participants included in the study, 213 (54.61%) were identified as genotype 3 positive, 78 (20%) as genotype 1 positive, 6 (1.53%) as genotype 6 positive, and the remaining 93 (23.85%) samples were unclassified due to low/undetected viral load. In this study, we detected the highest percentage (30.89%) of genotype 3 HCV in patients aged 51 to 60 years. The results suggested that genotype 3 HCV is frequently present in Bangladesh and it is usually responses better to interferon therapy. However, genotype 1 and 6 HCV have also been found circulating in this country, which demands longer treatments and effective control measures.

Keywords

genotypes - cirrhosis - hepatocellular carcinoma - reverse transcription - cDNA - antiviral therapies - viral load

Author Contributions

This work was performed in collaboration between all authors. Ahmed Abu Rus'd designed and supervised the study, and Md. Arifur Rahman and Md. Monirul Islam performed the research work and performed the statistical analysis. Mohammad Ariful Islam, Md. Eunus Ali, Farhana Afroze, and Mohammad Shamim Hossain contributed technical assistance in the study.




Publication History

Article published online:
07 August 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018; 6 (13) 589-599
    CrossrefPubMedGoogle Scholar
  • 2 Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39 (04) 1147-1171
    CrossrefPubMedGoogle Scholar
  • 3 Ashraf H, Alam NH, Rothermundt C. et al. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010; 10: 208
    CrossrefPubMedGoogle Scholar
  • 4 Rockstroh J, Grint D. et al. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected?. J Int AIDS Soc 2012; 15 (04) 18116
    Google Scholar
  • 5 Islam MS, Miah MR, Roy PK. et al. Genotypes of hepatitis C virus infection in Bangladeshi population. Mymensingh Med J 2015; 24 (01) 143-151
    PubMedGoogle Scholar
  • 6 Mahtab MA, Rahman S, Karim MF. et al. Epidemiology of hepatitis B virus in Bangladeshi general population. Hepatobiliary Pancreat Dis Int 2008; 7 (06) 595-600
    PubMedGoogle Scholar
  • 7 Azim T, Bogaerts J, Yirrell DL. et al. Injecting drug users in Bangladesh: prevalence of syphilis, hepatitis, HIV and HIV subtypes. AIDS 2002; 16 (01) 121-123
    CrossrefPubMedGoogle Scholar
  • 8 Rahman M, Hossain ME, Afrad MH. et al. Hepatitis C virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh. J Med Virol 2018; 90 (02) 383-387
    CrossrefPubMedGoogle Scholar
  • 9 IEDCR; ICDDRB. . National HIV Serological Surveillance 2011, Bangladesh: 9th Round Technical Report. Dhaka, Bangladesh: National AIDS/STD Program (NASP), Directorate General of Health Services, Ministry of Health and Family Welfare, Government of the People's Republic of Bangladesh; 2011
  • 10 Yee LJ, Weiss HL, Langner RG, Herrera J, Kaslow RA, van Leeuwen DJ. Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillance. BMC Infect Dis 2001; 1: 8
    CrossrefPubMedGoogle Scholar
  • 11 Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C virus genetic variability, human immune response, and genome polymorphisms: which is the interplay?. Cells 2019; 8 (04) 305
    CrossrefPubMedGoogle Scholar
  • 12 Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic diversity and selective pressure in hepatitis C virus genotypes 1–6: significance for direct-acting antiviral treatment and drug resistance. Viruses 2015; 7 (09) 5018-5039
    CrossrefPubMedGoogle Scholar
  • 13 Islam MJ, Habib MA. , et al. Prevalence of Hepatitis C Virus Genotypes in Bangladesh. Paper presented at: Proceeding of the 13th Annual Scientific Conference ICDDRB Dhaka. March 14–17, 2011; Dhaka, Bangladesh
  • 14 Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22 (34) 7824-7840
    CrossrefPubMedGoogle Scholar
  • 15 Petruzziello A, Sabatino R, Loquercio G. et al. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019; 14 (02) e0212033
    CrossrefPubMedGoogle Scholar
  • 16 Messina JP, Humphreys I, Flaxman A. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61 (01) 77-87
    CrossrefPubMedGoogle Scholar
  • 17 Jobayer M, Afroz Z. et al. Hepatitis: knowledge and awareness among the infected population. Bangladesh Med Res Counc Bull 2017; 43 (03) 126-130
    CrossrefGoogle Scholar
  • 18 Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13 (02) 223-235
    CrossrefPubMedGoogle Scholar
  • 19 Navaneethan U, Kemmer N, Neff GW. Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol 2009; 2 (05) 287-302
    CrossrefPubMedGoogle Scholar
  • 20 Nouroz F, Shaheen S. et al. An overview on hepatitis C virus genotypes and its control. Egypt J Med Hum Genet 2015; 16: 291-298
    CrossrefGoogle Scholar
  • 21 Lee YS, Yoon SK, Chung ES. et al. The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C. J Korean Med Sci 2001; 16 (05) 585-591
    CrossrefPubMedGoogle Scholar
  • 22 Forns X, Maluenda MD, López-Labrador FX. et al. Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. J Clin Microbiol 1996; 34 (10) 2516-2521
    CrossrefPubMedGoogle Scholar
  • 23 Nagayama K, Kurosaki M, Enomoto N, Miyasaka Y, Marumo F, Sato C. Characteristics of hepatitis C viral genome associated with disease progression. Hepatology 2000; 31 (03) 745-750
    CrossrefPubMedGoogle Scholar
  • 24 Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138 (02) 447-462
    CrossrefPubMedGoogle Scholar
  • 25 Pawlotsky JM, Prescott L, Simmonds P. et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997; 35 (07) 1734-1739
    CrossrefPubMedGoogle Scholar
  • 26 Frank C, Mohamed MK, Strickland GT. et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355 (9207): 887-891
    CrossrefPubMedGoogle Scholar
  • 27 Albadalejo J, Alonso R, Antinozzi R. et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 1998; 36 (04) 862-865
    CrossrefPubMedGoogle Scholar
  • 28 Ali S, Ahmad A, Khan RS. et al. Genotyping of HCV RNA reveals that 3a is the most prevalent genotype in Mardan, Pakistan. Adv Virol 2014; 2014: 606201
    PubMedGoogle Scholar
  • 29 Ali A, Nisar M, Ahmad H, Saif N, Idrees M, Bajwa MA. Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan. Virol J 2011; 8: 466
    CrossrefPubMedGoogle Scholar
  • 30 Bell H, Hellum K, Harthug S. et al. Genotype, viral load and age as independent predictors of treatment outcome of interferon-α 2a treatment in patients with chronic hepatitis C. Construct group. Scand J Infect Dis 1997; 29 (01) 17-22
    CrossrefPubMedGoogle Scholar
  • 31 Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57 (04) 1333-1342
    CrossrefPubMedGoogle Scholar